Skip to content

Trilogy EvoRecalls & reported problems across all models

Respironics, Inc. · 20 models in the FDA device registry

Data updated Oct 16, 2026 from official FDA records · Editorial policy

12 open recalls name at least one Trilogy Evo model. Check whether yours is affected in the recall details, and contact the manufacturer or your healthcare provider.

Adverse event reports
5,473
Deaths reported
61
Injuries reported
42
Recalls
12

We found 20 models of Trilogy Evo by Respironics, Inc. in the FDA's device registry (GUDID). Together they are named in 5,473 adverse event reports in the FDA's MAUDE database, received between Sep 9, 2020 and Sep 30, 2026 — classified as 61 deaths, 42 injuries, 5,370 malfunctions.

The most frequently reported specific device problem is “Electrical /Electronic Property Problem” (2,229 reports).

12 FDA recall records name at least one of these models by its device identifier, 12 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event. Widely used products collect more reports, so totals can't be used to compare products or estimate failure rates. Only reports that name a model's exact device identifier are counted. What reports can and can't tell you · How this data works

Reports received per month, all models

Nov 2023: 124 reportsDec 2023: 104 reportsJan 2024: 122 reportsFeb 2024: 100 reportsMar 2024: 106 reportsApr 2024: 101 reportsMay 2024: 94 reportsJun 2024: 81 reportsJul 2024: 78 reportsAug 2024: 36 reportsSep 2024: 43 reportsOct 2024: 77 reportsNov 2024: 51 reportsDec 2024: 58 reportsJan 2025: 50 reportsFeb 2025: 60 reportsMar 2025: 56 reportsApr 2025: 32 reportsMay 2025: 86 reportsJun 2025: 88 reportsJul 2025: 79 reportsAug 2025: 32 reportsSep 2025: 46 reportsOct 2025: 31 reportsNov 2025: 42 reportsDec 2025: 90 reportsJan 2026: 41 reportsFeb 2026: 47 reportsMar 2026: 60 reportsApr 2026: 57 reportsMay 2026: 66 reportsJun 2026: 103 reportsJul 2026: 0 reportsAug 2026: 3 reportsSep 2026: 34 reportsOct 2026: 0 reports202420252026124
Last 36 months. The most recent month may be incomplete.

Trilogy Evo recalls

FDA recall records that name at least one of these models by its device identifier, newest first. Each recall usually covers specific models or lots, so check the details.

  1. Oct 7, 2024Open, Classified

    Potential for in-line nebulizer configuration in certain locations to result in aerosol deposit accumulation on the device's internal flow sensor, which could lead to inaccurate flow measurements.

    Z-0291-2025 · Root cause: Device Design · names 12 of these models · Recall details · FDA record ↗

  2. Oct 7, 2024Open, Classified

    Potential for in-line nebulizer configuration in certain locations to result in aerosol deposit accumulation on the device's internal flow sensor, which could lead to inaccurate flow measurements.

    Z-0290-2025 · Root cause: Device Design · names 7 of these models · Recall details · FDA record ↗

  3. Jul 16, 2024Open, Classified

    Firm has released a mandatory software update Version 1.05.10.00 and a User Manual addendum for affected ventilators. These updates resolve safety issues identified in earlier recalls.

    Z-2944-2024 · Root cause: Device Design · names 18 of these models · Recall details · FDA record ↗

  4. Mar 19, 2024Open, Classified

    Potential for sudden loss of ventilation due to Battery Depleted or Loss of Power alarm while unit has sufficient power.

    Z-1504-2024 · Root cause: Device Design · names 11 of these models · Recall details · FDA record ↗

  5. Mar 19, 2024Open, Classified

    Potential for sudden loss of ventilation due to Battery Depleted or Loss of Power alarm while unit has sufficient power.

    Z-1503-2024 · Root cause: Device Design · names 4 of these models · Recall details · FDA record ↗

  6. Mar 19, 2024Open, Classified

    Potential for sudden loss of ventilation due to Battery Depleted or Loss of Power alarm while unit has sufficient power.

    Z-1502-2024 · Root cause: Device Design · names 3 of these models · Recall details · FDA record ↗

  7. Nov 27, 2023Open, Classified

    The following was missing from the Contraindications Statement: The AVAPS-AE therapy mode is contraindicated for invasive use and patients less than 10 kg. The AVAPS feature is contraindicated for patients less than 10 kg. Potential harms if devices are used on contraindicated patients include barotrauma, hypoventilation/hypercapnia, and rebreathing of excessive CO2.

    Z-0638-2024 · Root cause: Device Design · names 14 of these models · Recall details · FDA record ↗

  8. May 25, 2023Open, Classified

    There are errors present in the Korean Instructions For Use where the word "invasive," was incorrectly translated to "noninvasive".

    Z-2106-2023 · Root cause: Under Investigation by firm · Recall details · FDA record ↗

  9. May 1, 2023Open, Classified

    Environmental debris may accumulate on the internal machine flow sensor causing partial occlusion which may impact accurate delivery of pressure, volume, or flow. A malfunction caused by this issue can result in patient harm up to hypoxemia if not addressed by the care provider.

    Z-1650-2023 · Root cause: Under Investigation by firm · names 3 of these models · Recall details · FDA record ↗

  10. May 1, 2023Open, Classified

    Environmental debris may accumulate on the internal machine flow sensor causing partial occlusion which may impact accurate delivery of pressure, volume, or flow. A malfunction caused by this issue can result in patient harm up to hypoxemia if not addressed by the care provider.

    Z-1649-2023 · Root cause: Under Investigation by firm · names 4 of these models · Recall details · FDA record ↗

  11. Mar 1, 2023Open, Classified

    The accuracy of delivered oxygen may deviate below the required tolerance of 5% from setpoint when providing high concentration oxygen therapy. Additionally, if equipped, the internal FiO2 sensor may indicate a value higher than the device is actually delivering. This may lead to under delivery of oxygen.

    Z-1287-2023 · Root cause: Under Investigation by firm · names 7 of these models · Recall details · FDA record ↗

  12. Dec 22, 2021Open, Classified

    Philips has identified a specific lot of non-conforming material manufactured by one of its suppliers. A Philips supplier incorrectly used polyester-based polyurethane (PE-PUR) sound abatement foam, a non-conforming material in the devices and repair kits. PE-PUR foam may degrade into particles which may enter the device s air pathway and be ingested or inhaled by the user. The foam degradation may be exacerbated by use of unapproved cleaning methods such as unapproved ozone cleaners, and the PE-PUR foam may off-gas certain chemicals during initial use of the device.

    Z-0493-2022 · Root cause: Mixed-up of materials/components · names 2 of these models · Recall details · FDA record ↗

Most reported Trilogy Evo problems

Device problems

  • Electrical /Electronic Property Problem2,229
  • Mechanical Problem1,127
  • Circuit Failure877
  • Contamination702
  • Failure to Recalibrate417
  • Display or Visual Feedback Problem319
  • Battery Problem317
  • Device Sensing Problem271

Patient problems

  • No Clinical Signs, Symptoms or Conditions5,341
  • Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available35
  • Insufficient Information33
  • Dyspnea11
  • Unspecified Respiratory Problem11
  • Respiratory Arrest10
  • Cardiac Arrest7
  • Cyanosis7

Trilogy Evo models

20 models, most reported first. Each model has its own page with its reports, recalls and device details.

Recent Trilogy Evo adverse event reports

The 15 most recent reports across all models, in the reporter's own words as published by the FDA.

Other Respironics, Inc. products

All Respironics, Inc. devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page